Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation

Biochemical Pharmacology

Volumn 58, Issue 11, 1999, Pages 1765-1773

  Ruggiero Lopez, Daniel ^a   Lecomte, Marc ^a   Moinet, Gérard ^b   Patereau, Gérard ^b   Lagarde, Michel ^a   Wiernsperger, Nicolas ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Lipha Sa   (France)

Author keywords

Advanced glycation end products; Carbonyl stress; Dicarbonyl compounds; Glycoxidation; Metformin; Triazepin

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ALBUMIN; AMINOGUANIDINE; CARBONYL DERIVATIVE; GLYOXAL; GUANIDINE DERIVATIVE; METFORMIN; METHYLGLYOXAL;

ARTICLE; CHEMICAL REACTION KINETICS; DRUG INHIBITION; DRUG STRUCTURE; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; SYNTHESIS; ULTRAFILTRATION; VASCULAR DISEASE;

ANIMALS; AZEPINES; CATTLE; ENZYME INHIBITORS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; GUANIDINES; HYPOGLYCEMIC AGENTS; METFORMIN; PYRUVALDEHYDE; SERUM ALBUMIN;

EID: 0032702642     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00263-4     Document Type: Article

References (29)

1. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation Biochemical, biologic, and clinical implications for diabetes and aging . Lab Invest. 70:1994;138-151.
2. Bucala R., Cerami A., Vlassara H. Advanced glycosylation end products in diabetic complications. Diabetes Rev. 3:1995;258-268.
3. Glomb M.A., Monnier V.M. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem. 270:1995;10017-10026.
4. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.L., Stern D. Cellular receptors for advanced glycation end products. Arterioscler Thromb. 14:1994;1521-1528.
5. Wells-Knecht K.J., Brinkman E., Wells-Knecht M.C., Litchfield J.E., Ahmed M.U., Reddy S., Zyzak D.V., Thorpe S.R., Baynes J.W. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant. 11:(Suppl 5):1996;41-47.
6. Zyzak D.V., Richardson J.M., Thorpe S.R., Baynes J.W. Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch Biochem Biophys. 316:1995;547-554.
7. Wells-Knecht K.J., Zyzak D.V., Litchfield J.E., Thorpe S.R., Baynes J.W. Mechanism of autoxidative glycosylation Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose . Biochemistry. 34:1995;3702-3709.
8. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation. Biochem J. 256:1988;205-212.
9. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 271:1996;9982-9986.
10. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci. 87:1994;21-29.
11. Thornalley P.J. Methylglyoxal, glyoxalases and the development of diabetic complications. Amino Acids. 6:1994;15-23.
12. Lo T.W.C., Westwood M.E., McLellan A.C., Selwood T., Thornalley P.J. Binding and modification of proteins by methylglyoxal under physiological conditions. J Biol Chem. 269:1994;32299-32305.
13. Shamsi F.A., Partal A., Sady C., Glomb M.A., Nagaraj R.H. Immunological evidence for methylglyoxal-derived modifications in vivo. J Biol Chem. 273:1998;6928-6936.
14. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
15. Lo T.W.C., Selwood T., Thornalley P.J. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol. 48:1994;1865-1870.
16. Hirsch J., Petrakova E., Feather M.S. The reaction of some dicarbonyl sugars with aminoguanidine. Carbohydr Res. 232:1992;125-130.
17. Ou P., Wolff S.P. Aminoguanidine A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro . Biochem Pharmacol. 46:1993;1139-1144.
18. Wiernsperger N and Rapin JR, Metformin-insulin interactions: From organ to cell. Diabetes Metab Rev11: S3-S12, 1995.
19. Njoroge F.G., Sayre L.M., Monnier V.M. Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr Res. 167:1987;211-220.
20. Tanabe S., Sakaguchi T. Reaction of guanidines with α-diketones. VL. Structures of fluorescent products of biguanides with 9,10-phenanthraquinone. Chem Pharm Bull (Tokyo). 26:1978;423-428.
21. Shipanova I.N., Glomb M.A., Nagaraj R.H. Protein modification by methylglyoxal Chemical nature and synthetic mechanism of a major fluorescent adduct . Arch Biochem Biophys. 344:1997;29-36.
22. Yim H., Kang S., Hah Y., Chock B., Yim M. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. J Biol Chem. 270:1995;28228-28233.
23. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications. Diabetes. 48:1999;1-9.
24. Ray P. Complex compounds of biguanides and guanylureas with metallic elements. Chem Rev. 61:1961;313-359.
25. Tanaka Y., Iwamoto H., Onuma T., Kawamori R. Inhibitory effect of metformin on formation of advanced glycation end products. Curr Ther Res Clin Exp. 58:1997;693-697.
26. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
27. Colantuoni A., Bertuglia S., Donato L. Effects of metformin on microvascular permeability in diabetic syrian hamsters. Diabetes Metab. 14:1988;549-553.
28. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 352:1998;854-865.
29. Beisswenger P.J., Howell S.K., Touchette A.D., Lal S., Szwergold B.S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 48:1999;198-202.